What Will USPTO-FDA Collaboration Look Like? Stakeholders To Weigh In On Proposed Initiatives

Agencies are holding public ‘listening session’ to get input on method of use patents and ‘skinny labeling,’ REMS patenting, PTAB proceedings and other topics.

FDA and USPTO
USPTO and FDA holding public meeting to get input on areas for collaboration • Source: Nielsen Hobbs; the Pink Sheet|Shutterstock images

The US Patent and Trademark Office and US Food and Drug Administration are working out how they will collaborate to promote greater access to medicines and increase competition. Industry representatives, patients, payors and other stakeholders will get a chance to provide feedback on potential actions the agencies may take to achieve this goal.

The agencies are holding a public “listening session” on 19 January to obtain input on their joint collaboration initiatives. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

ACIP ‘Pivot’ May Mean Variable Private Coverage For New Vaccines, Higher Copays

 
• By 

Clarity on payer responses to controversial vaccine recommendations from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices may be coming.

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.

Price Inflation Rebates: Biden Policies Add Teeth To Trump’s Pharma Tariff Threat

 
• By 

Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.

More from Pink Sheet

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.